Brief: JCR Pharmaceuticals Plans To Start Clinical Trial In Japan In First Half Of FY24
02/07/2024 12:38
July 2 (Reuters) - JCR Pharmaceuticals Co Ltd 4552.T :
* MEDIPAL AND JCR ANNOUNCE COMPLETION OF CLINICAL TRIAL
NOTIFICATION PROCESS IN JAPAN FOR PHASE I/II STUDY OF JR-446 FOR
MUCOPOLYSACCHARIDOSIS TYPE IIIB
* JCR PHARMACEUTICALS CO LTD - PLAN TO START CLINICAL TRIAL
IN
JAPAN IN FIRST HALF OF FY2024 (APRIL TO SEPTEMBER)
Source text for Eikon: ID:nBw12lqq4a
Further company coverage: 4552.T
((Reuters.Briefs@thomsonreuters.com;))
Recent news on JCR Pharmaceuticals
See all newsBrief: JCR Pharmaceuticals Receives Marketing Authorization In Kuwait For Izcargo
Italfarmaco And Jcr Pharmaceuticals Enter Into Exclusive License Agreement For Jr-141 In United States, Europe, And Latin America
Brief: Jcr Pharmaceuticals Receives Orphan Drug Designation For Givinostat In Japan
Brief: Medipal & JCR Dose First Patient In Global Phase I/II Trial OF JR-446 For Mucopolysaccharidosis Type IIIB
Table: Jcr Pharmaceuticals -Q1 group results